



## ABIVAX confirms trading resumption

**Paris, May 2<sup>nd</sup>, 2017 at 7:00am CEST** – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, confirms the resumption of trading effective as of Euronext Paris market opening at 9:00am CEST.

As a reminder, trading was suspended, as requested by the company and in agreement with the AMF (French Market Authority), on Friday April, 28<sup>th</sup> 2017 at 11:29am (CEST).

The company will also disclose top line results of ABX464-004, the 2nd Phase IIa of ABX464, its lead drug candidate in the treatment of HIV, today before market opening.

**About ABIVAX** ([www.abivax.com](http://www.abivax.com))

ABIVAX is an innovative biotechnology company focused on targeting the immune system to eliminate viral disease. To do this ABIVAX leverages three technology platforms for drug discovery: antiviral, immune enhancing and polyclonal antibodies. ABX464, its most advanced compound, is currently in Phase II clinical trials to test its ability to enable a functional cure for patients with HIV/AIDS. It is a first-in-class oral small antiviral molecule which blocks HIV replication through a unique mechanism of action and, separately, also has a strong anti-inflammatory effect. In addition, ABIVAX is advancing a clinical stage immune enhancer as well as multiple preclinical candidates against additional viral targets (i.e. Chikungunya, Ebola, Dengue); several of these compounds are planned to enter clinical development within the next 18 months. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX).

More information on the company is available at [www.abivax.com](http://www.abivax.com).

Follow us on Twitter @ABIVAX\_

### Contacts

#### ABIVAX

##### Finance

Didier Blondel

[didier.blondel@abivax.com](mailto:didier.blondel@abivax.com)

+33 1 53 83 08 41

#### Communication Agency

##### ALIZE RP

Caroline Carmagnol/Margaux Pronost

[abivax@alizerp.com](mailto:abivax@alizerp.com)

+33 6 64 18 99 59 / +33 1 44 54 36 65

#### Investors

##### LifeSci Advisors

Chris Maggos

[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)

+41 79 367 6254